795 results on '"Leis, Jose F."'
Search Results
2. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
3. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia
4. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism
5. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
6. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
7. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
8. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
9. Hematopoietic Stem Cell Sources and Donor Selection
10. Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
11. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
12. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
13. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families
14. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
15. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
16. Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
17. Parkinsonism as a late presentation of lymphomatosis cerebri following high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma
18. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
19. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma
20. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections
21. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
22. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
23. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia
24. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
25. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
26. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32
27. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
28. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis
29. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
30. Hematopoietic Stem Cell Sources and Donor Selection
31. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
32. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial
33. Data from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
34. Supplementary Table 5 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
35. Supplementary Table 3 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
36. Supplementary Figure 1 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
37. Supplementary Table 1 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
38. Supplementary Table 4 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
39. Supplementary Table 2 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
40. DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
41. Quality of the control arms in randomized trials of chronic lymphocytic leukemia enrolling in the USA: A systematic review
42. Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis
43. Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial
44. Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population
45. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
46. Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
47. Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations
48. Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis
49. Quality of Control Arms in Randomized Trials of Chronic Lymphocytic Leukemia Enrolling in the USA: A Systematic Review
50. Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.